Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-27 16:16:47 - browse：522

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Illumina names Agilent executive as new CEO

WSS

Medicaid rebukes states for mistakenly disenrolling children

The 10 drugs up first for Medicare price negotiation

Stem cell treatment guidelines are released by FDA

New Ultima Genomics DNA sequencer can read genome for $100

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Cognito secures funding to test medical device for Alzheimer's

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

In Memoriam: Notable people who died in 2023

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Walensky prepares to leave CDC — and Congress — behind

Biden administration opens offers in Medicare drug price negotiations

As demand for Covid shots wanes, Moderna seeks its next success

Novo Nordisk to expand supply of Wegovy for U.S. patients

Psychedelics group wrestles with new pharma identity

Woodcock on FDA’s accelerated approval and her next chapter

Heart attack and stroke risk calculators need revising

Listen: Biogen's potential pivot, & Illumina's next chapter

leisure time

New Ultima Genomics DNA sequencer can read genome for $100

FDA drug safety: Singulair case shows systemic surveillance flaws

Vertigo drug brings hope for rare neuron disorder, Niemann

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

ARCH Venture Partners is raising $3 billion for a life sciences fund

Woodcock on FDA’s accelerated approval and her next chapter

hotspot

Wikipedia

entertainment

explore